COVID-19 brought to prominence its peculiar symptoms such as   anosmia and ageusia (loss of smell and taste). This potentially will lead to the emergence of exploiting the olfactory bulb and trigeminal nerve route to deliver the next generation drugs for treating chronic neurodegenerative diseases, neuropsychiatry and incurable brain tumours. CNS drugs continue to plagued by poor absorption as less than 5% bioavailability is where most CNS drugs stands at present. This is due to presence of tight junctions, the worrisome ABC drug transporters such as ABCB1(P-gp) and ABCG2 (BCRP) in the Blood Brain Barrier (BBB) limiting CNS drugs uptake among other factors. Therefore, CNS chronic diseases therapeutics is largely an unmet clinical need space requiring novel approaches and medicines.

To combat this poor CNS drugs efficacy issues, our R&D company  has in the pipeline novel  polymeric and nanoparticles-loaded actives as  lead candidate next generation experimental  therapies for Alzheimer dementia( AFXI-02), Parkinson disease (AFXI-03), Incurable Brain Tumour  like Gliomas, Medulloblastomas( AFXI-04, AFXI-05), Depression and  Anxiety( AFXI-06), all  developed largely as nose to brain formulations to circumvent poor BBB absorption problems, ensure  better tolerability and compliance for patients suffering from these chronic conditions. Our lead formulation candidates are being developed as dry spray powder nasal sprays, liquid nasal sprays, Intravenous and Intrathecal formulations. 

In development of lead candidates, we are utilizing 4 vehicles for the delivery of the choice novel therapies namely: Surfactants, Polymers, Nanoparticles with fluorescence and Nanoparticles carriers without fluorescence. The nanoparticles carriers were developed using microfluidic approach. For the dry powder nasal and liquid nasal sprays, we are going to evaluate their deposition using nasal cast built from CT scans of several human subjects to assess deposition of the drug in the essential parts of nasal epithelium, turbinate region, olfactory bulb as well as the desired neurons in specific regions of the brain to show the lead candidate formulation have gone pass the tight junctions to reach the desired target regions of the brain. 

Our lead sprays formulations spray angle of administration, their particle sizes, particle velocity will be documented for publication. Our neuronal cell lines, animals biomarkers PCR assessments using both plasma and biopsied diseased-modelled animal  brain tissues, imaging and phenotypic characteristics  data we also  intend to  publish in peer- reviewed journals in the future; with details of the nanoparticles utilised  encapsulation ratio, charge and Z potential data, animal studies biomarkers and safety profile  data inclusive for each lead candidate formulation.

To be added